Sessioni Poster


Antibacterial and antiviral chemotherapy. Anti-HCV and anti-HIV drugs

Thursday, October 26th / 19.00-21.00
13HEPATITIS C VIRUS (HCV) INFECTION EVALUATION OF PREVALENCE AND RELATED COSTS IN THE LOCAL HEALTH UNIT N.2, DISTRICT OF TREVISO
Bellin A.., Giusti P.., Schiavon A.., Franchin G.., Bettiol A.., Bolcato J.., Pirolo R.., Chinellato A..
37CLINICAL PHARMACOLOGICAL ADVICE (CPA) FOR OPTIMIZATION OF LINEZOLID THERAPY IN HOSPITALIZED PATIENTS WITH MULTIDRUG RESISTANT GRAM-POSITIVE INFECTIONS
Cojutti P.., Pea F.., Merelli M.., Bassetti M.., Baraldo M..
63Interactions between antiretroviral drugs and human Arginase 1.
Lisi L., Pizzoferrato M., Miscioscia F., Topai A., Navarra P.
77Healthcare resources use in patients with Human Virus Infection (HIV). Real-world evidence from Italian administrative databases.
Perrone V., Sangiorgi D., Buda S., Degli Esposti L.
78Burden of comorbidities in HCV patients only and HIV-HCV co-infected patients in a real- world setting: retrospective study.
Perrone V., Sangiorgi D., Buda S., Degli Esposti L.
121A NEW UHPLC-MS/MS METHOD FOR THE EVALUATION OF THE INTRACELLULAR PHARMACOKINETIC OF THE NEW DIRECT ANTIVIRAL AGENTS (DAA) IN HCV POSITIVE PATIENTS SAMPLES
Ariaudo A., Favata F., Boglione L., Gontero E., De nicolò A., Carcieri C., Simiele M., Cusato J., Di perri G., D'avolio A.
236In vitro and in vivo antibacterial activity of novel dual bacterial DNA type II topoisomerase inhibitors (NBTIs)
Di Matteo A., D'Atanasio N., Apicella C., Ombrato R., Magarò G., Milanese C., Di Giorgio FP., Tongiani S.
323Pharmacokinetics of darunavir/cobicistat in an Italian observational, multicenter, prospective study (The STart Of REzolsta "ST.O.RE" study - TMC114FD1HTX4003).
Gori A., Focà E., Antinori A., Vergori A., Maserati R., Rusconi S., Di cristo V., Uglietti A., Termini R., Mancusi D.
350miRNA-218 TARGETS LIPIN-1 AND GLUT-4 GENES IN LOPINAVIR/RITONAVIR TREATED 3T3-L1 CELLS
Molteni L., Bresciani E., Saletti C., Squillace N., Torsello A., Rizzi L., Gori A., Locatelli V.